In Silico Exploration of Aryl Halides Analogues as Checkpoint Kinase 1 Inhibitors by Using 3D QSAR, Molecular Docking Study, and ADMET Screening

Adib Ghaleb1*, Adnane Aouidate1, Mohammed Bouachrine2, Tahar Lakhlifi1, Abdelouahid Sbai3

1Faculty of Science, Moulay Ismail University, Meknes, Morocco.
2EST, Moulay Ismail University, Meknes, Morocco.

Abstract

Purpose: In this review, a set of aryl halides analogs were identified as potent checkpoint kinase 1 (Chk1) inhibitors through a series of computer-aided drug design processes, to develop models with good predictive ability, highlight the important interactions between the ligand and the Chk1 receptor protein and determine properties of the new proposed drugs as Chk1 inhibitors agents.

Methods: Three-dimensional quantitative structure–activity relationship (3D-QSAR) modeling, molecular docking and absorption, distribution, metabolism, excretion and toxicity (ADMET) approaches are used to determine structure activity relationship and confirm the stable conformation on the receptor pocket.

Results: The statistical analysis results of comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) models that employed for a training set of 24 compounds gives reliable values of $Q^2$ (0.70 and 0.94, respectively) and $R^2$ (0.68 and 0.96, respectively).

Conclusion: Computer-aided drug design tools used to develop models that possess good predictive ability, and to determine the stability of the observed and predicted molecules in the receptor pocket, also in silico of pharmacokinetic (ADMET) results shows good properties and bioavailability for these new proposed Chk1 inhibitors agents.

Introduction

Quantitative structure–activity relationship (QSAR) methodology is an essential tool in modern medicinal chemistry try to relate the biological activity of a series of chemicals to their physicochemical and structural properties, relying on the concept that similar structures can have similar properties and when the differences between compounds are high, the correlation of their properties with activities becomes hard, whereas the correlations between highly similar molecules are easier.2 The applications of QSAR to molecular modeling and drug discovery has led to developed tools in computational chemistry field, and have been used to predict a large number of biological endpoints and shed light on the mechanism of action, whether it is toxicological or pharmacological.

This study carried out comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) to predict the activity of 24 aromatic halides compounds present cytotoxicity activities retrieved from literature,2-4 and propose new competent drugs.

To study the stability of predicted compounds in serine-threonine kinase has an important role in repairing DNA damage and prevents cells from entering mitosis where DNA damage exists (Chk1 receptor) as inhibitor agents,5 a surflex-docking was performed. Also we calculated total scoring (energy affinity) and defined the stable conformation of the ligands and its interactions in the receptor pocket (PDB entry code: 6FC8). Moreover we performed an in silico study concerning the absorption, distribution, metabolism, excretion and toxicity (ADMET), which has created a unique interdisciplinary interface between medicinal chemist and clinicians. These crucial proprieties are usually used to finalize clinical success of a drug candidate, because it has been estimated that 50% of drugs fail as results of poor bioavailability.

For a molecule crossing a membrane through passive diffusion, reasonable permeability can be made using molecular properties, such as lipophilicity or hydrogen bonding. For many drugs, this first requires metabolism or biotransformation, takes place in the gut.
In Silico Exploration of Aryl Halides Analogues as Checkpoint Kinase 1 Inhibitors

Advanced Pharmaceutical Bulletin, 2019, Volume 9, Issue 1

Materials and Methods
A database of 24 compounds consisted of aryl halides analogs, the data set was split into two sets, 19 compounds were selected as training set and 5 compounds were selected as test set, based on a random selection to evaluate the ability of the model obtained. The structures of both the training and test sets are given in Table 1, while experimental and predicted biological activities are presented in Table 2. These data sets were used to construct 3D-QSAR (CoMFA and CoMSIA) models and to analyses their physicochemical properties. MIC activity was measured previously in μM/mL, we converted them to pLC values as Log(1/LC). The pLC values presented in Table 2 were used as the dependent variables in all subsequently developed partial least squares (PLS) models.

The three-dimensional structure building of molecules and the optimizations were performed using Sybyl 2.0 program package, Discovery Studio, and the program MOLCAD. ADMET properties are determined by Admetsar and pKCSM predictors.

Minimization and alignment
All structures are sketched with SYBYL and optimized with Tripos force field, Gasteiger Huckel charges and with gradient convergence criteria 0.01 kcal/mol. The annealing simulation of structures is performed with 20 cycles. All molecules are aligned with common core, using simple alignment method, while active compound 24 is used as template. The superimposed structures are shown in Figure 1.

3D QSAR
Electrostatic, hydrophobic and steric fields contributions are explored to understand predicted activities, relying on CoMFA, CoMSIA studies and molecular alignment strategy, as previously described in literature.

CoMSIA and CoMFA
Relying on molecular alignment, CoMFA and CoMSIA approaches are applied to determine and analyze electrostatic, hydrophobic, and steric effects. Moreover, steric and electrostatic interaction fields are calculated at each intersection point of a regularly spaced grid of 2 Å, and default value of 30 kcal/mol is set as a maximum electrostatic and steric energy cutoff. Regression analysis used is the cross validation PLS method. The minimum column filtering is set to 2.0 kcal/mol, and the final non cross validated model is developed by optimal number of components with the highest R² value and the smallest value of standard error predictions. Moreover, the external

Table 1. List of 24 halogen containing hydroxy and amino substituted aromatic compounds

| Comp | X  | Y  | R1    | R2    | R3     | R4 | R5 | R6 | R7 | R8 |
|------|----|----|-------|-------|--------|----|----|----|----|----|
| 1    | C  | C  | H     | OH    | CH₂CO  | H  | Br | H  | -  | -  |
| 2    | C  | C  | Br    | OH    | CH₂CO  | H  | H  | H  | -  | -  |
| 3    | C  | C  | Br    | OH    | CH₂CO  | H  | Br | OH | -  | -  |
| 4    | C  | C  | Br    | OH    | CH₂CO  | OH | Br | H  | -  | -  |
| 5    | C  | C  | Br    | H     | CH₂CO  | H  | Br | OH | -  | -  |
| 6    | C  | C  | Br    | H     | CH₂CICICO | H | Br | OH | -  | -  |
| 7    | C  | C  | Br    | H     | Cl    | H   | Cl | OH | -  | -  |
| 8*   | C  | C  | Br    | H     | CH₂CO  | H  | Br | NH₃ | -  | -  |
| 9*   | C  | C  | Br    | H     | CH₂CICO | H | Br | NH₃ | -  | -  |
| 10*  | C  | C  | Br    | H     | Cl    | H   | Br | NH₃ | -  | -  |
| 11   | C  | C  | H     | Br    | OH    | Br  | H  | Br | -  | -  |
| 12   | C  | C  | H     | Br    | OH    | Br  | H  | NO₂ | -  | -  |
| 13   | C  | C  | H     | Br    | OH    | H   | H  | NO₂ | -  | -  |
| 14*  | C  | C  | H     | Br    | NH₃   | Br  | H  | Br | -  | -  |
| 15*  | C  | C  | H     | Br    | NH₃   | Cl  | H  | Br | -  | -  |
| 16   | C  | C  | H     | Br    | NH₃   | Br  | H  | NO₂ | -  | -  |
| 17   | C  | C  | H     | Br    | NH₃   | Cl  | H  | NO₂ | -  | -  |
| 18   | C  | N  | -     | OH    | Br    | H   | Br | CH₂ | -  | -  |
| 19   | N  | N  | -     | NH₃   | -     | H   | Br | H  | -  | -  |
| 20   | C  | N  | -     | NH₃   | Br    | H   | H  | NH₃ | -  | -  |
| 21   | C  | N  | -     | NH₃   | Cl    | H   | Cl | H  | -  | -  |
| 22   | -  | C  | Cl    | Cl    | OH    | H   | H  | H  | -  | -  |
| 23   | -  | N  | -     | H     | H     | H   | Br | H  | Cl | OH |
| 24   | -  | N  | -     | H     | Cl    | H   | Cl | H  | H  | OH |

* Test set molecules.
validation \( r^2 \) was used to evaluate power of predictive model. Many CoMFA models were built considering permutations of molecules between training and test sets. The best model amongst them has been chosen, relying on high values of \( Q^2 \) and \( r^2 \), also with small standard error of estimate (SEE) value. The physicochemical properties for CoMSIA model have been adopted to avoid singularities at the atomic positions and dramatic changes of potential energy for grids being in the proximity of the surface. With the standard parameters and no arbitrary cutoff limits, five fields associated to five physicochemical properties were calculated.

**PLS analysis**

PLS method is a popular method used in deriving 3D-QSAR models, it is an extension of multiple regression analysis. In this rapport PLS method with leave-one-out (LOO) cross-validation is used to determine the optimal numbers of components relying on cross validation coefficient \( Q^2 \). Moreover, an external validation is performed using a test set of five molecules. The final analysis is carried out to get correlation coefficient \( R^2 \) and \( Q^2 \) values, while \( Q^2 \) determines the internal predictive ability of the model, and \( R^2 \) value evaluates the internal consistency of the model. Thus, the best QSAR model is chosen relying on a combination of \( Q^2 \) and \( R^2 \).

**Y-Randomization test**

The obtained models are validated by the Y-Randomization method. Y vector (-Log LC\(_{50}\)) is randomly shuffled for many times and after every iteration. This technique is carried out to eliminate the possibility of the chance correlation, if obtained values of the \( Q^2 \) and \( R^2 \) values, while \( Q^2 \) determines the internal predictive ability of the model, and \( R^2 \) value evaluates the internal consistency of the model. Thus, the best QSAR model is chosen relying on a combination of \( Q^2 \) and \( R^2 \).

**Molecular docking**

Surflex-Dock module is used for molecular docking. The crystal structures of Chk1 kinase domain is downloaded from Protein Data Bank (PDB ID: 2FC8). All water molecules in 2FC8 are deleted and the polar hydrogen atoms added. Protomol, is a computational representation of ligand that makes every potential interaction with binding site, applied to make molecular docking and

| No. | \( \text{pLC}_{50} \) | CoMFA Predicted | CoMFA Residuals | CoMSIA Predicted | CoMSIA Residuals |
|-----|----------------|-----------------|----------------|-----------------|-----------------|
| 1   | 1.24           | 0.940           | 0.3            | 0.919           | 0.321           |
| 2   | 1.25           | 1.125           | -0.125         | 1.101           | 0.149           |
| 3   | 0.39           | 0.662           | -0.272         | 0.683           | -0.293          |
| 4   | 0.49           | 0.743           | -0.253         | 0.782           | -0.292          |
| 5   | 0.73           | 0.947           | -0.217         | 0.697           | 0.033           |
| 6   | 0.03           | 0.124           | -0.094         | 0.109           | -0.079          |
| 7   | 0.49           | 0.452           | 0.038          | 0.357           | 0.133           |
| 8*  | 1.1            | 0.890           | 0.21           | 0.83            | 0.27            |
| 9*  | 0.3            | 0.172           | 0.128          | 0.163           | 0.137           |
| 10* | 0.48           | 0.526           | -0.046         | 0.408           | 0.072           |
| 11  | 0.27           | 0.253           | 0.017          | 0.180           | 0.203           |
| 12  | 1.12           | 1.288           | -0.16          | 1.225           | -0.105          |
| 13  | 0.98           | 1.340           | -0.36          | 0.969           | 0.011           |
| 14* | 0.6            | 0.591           | 0.009          | 0.490           | 0.11            |
| 15* | 0.83           | 0.661           | 0.169          | 0.619           | 0.211           |
| 16  | 1.74           | 1.487           | 0.253          | 1.522           | 0.218           |
| 17  | 1.79           | 1.535           | 0.235          | 1.650           | 0.14            |
| 18  | 1.01           | 1.100           | -0.09          | 1.23            | -0.22           |
| 19  | 0.26           | 0.40            | -0.14          | 0.33            | -0.07           |
| 20  | 0.54           | 0.6             | -0.06          | 0.52            | 0.02            |
| 21  | 0.65           | 0.59            | 0.06           | 0.77            | -0.12           |
| 22  | 2.37           | 2.216           | 0.154          | 2.293           | 0.077           |
| 23  | 1.61           | 1.736           | -0.146         | 1.601           | 0.009           |
| 24  | 2.6            | 2.478           | 0.122          | 2.213           | 0.367           |

**Figure 1**: The superposition and alignment of training data set using compound 24 as a template.
predict the binding modes. All protomols can be established by three ways: (1) automatic: Surflex-Dock figure out the largest cavity in the protein; (2) ligand-based: ligand in the same coordinate space as the receptor; (3) residues based: this type specifying residues in protein,\textsuperscript{22,23} all ligands are docked in the pockets for further analysis.

An automatic docking is applied; the 2FC8 structure was utilized in the subsequent docking experiments without energy minimization with other parameters established by default in the software. Total scores are expressed in \(-\log_{10}(K_i)\) units to present binding affinities. Then, Molecular Computer Aided Design program is employed to visualize binding modes and exhibits the surfaces of cavities.\textsuperscript{24,25} Moreover, Surflex-Dock scores, that represent binding energies, are used to determine ligand-receptor interactions of new predicted compounds. Each optimized conformation of every compound in the data set is energetically minimized using Tripos force field and Powell conjugated gradient algorithm with a convergence criterion of 0.05 kcal/mol and Gasteiger-Huckel charges.\textsuperscript{12}

**In silico ADMET study**

Drug discovery is a very complex and cost endeavor, divided into a series of stages including disease selection, target identification, lead or hit discovery, lead optimization, pre-clinical and clinical trials.\textsuperscript{26} In the past decade, many drug candidates have failed in late development stages. About 50% of drug failures can be attributed to unacceptable ADMET properties. This means that optimizing ADMET properties in early stage of drug discovery are widely used to reduce the high attrition rate. In recent years, a variety of medium to high-throughput in vitro ADMET screening methods have been developed. However, experimental evaluation of ADMET is still costly and time consuming. And still cannot meet the demands of drug screening and lead optimization. As the development of computer science and technology, in silico methods have been successfully applied to ADMET prediction.

In this review we focused on the development of ADMET prediction models for the excellent proposed compound.

**Discussion and Results**

**CoMFA results**

Results of Table 3 demonstrate that CoMFA model has high \(R^2\) (0.94), \(F\) (13.56) values and a small \(S_{cv}\) (0.2) as well as cross validation coefficient \(Q^2\) (0.70) with forth as optimum number of components. The external predictive capability of QSAR model is cross checked and it is validated using test sets. The five randomly selected test sets are optimized and aligned in the same manner as training sets. The external validation gave high value of \(r_{cv}^2\) (0.89) which indicates that prediction ability of CoMFA model is acceptable. The ration of steric to electrostatic contributions were found to be 60:40, which indicates that steric interactions are much more important than electrostatic.

**CoMSIA results**

3D-QSAR model was proposed based on CoMSIA descriptor to explain and predict quantitatively the hydrophobic, electrostatic, steric, donor and acceptor fields effects of substituents on anti-bacterial activity of 24 compounds. Different combinations of five fields were generated. The best proposed model of contains four fields (steric, electrostatic, hydrophobic, and acceptor), the correlation of cross-validated coefficient \(Q^2\) value of the training set and non-cross-validated correlation coefficient \(R^2\) of this model are 0.68 and 0.85, respectively. The optimal numbers of principal components used to generate the CoMSIA model are three which is reasonable, the standard error was 0.33.

Finally, the prediction ability of the predicted model is confirmed by using an external validation \(r_{ext}^2\) value that gave 0.96. These statistical results indicate good stability and the powerful predictive ability (Figure 2). Furthermore, the graphs showing the experimental and predicted pLC\(_{50}\) values for the total set used in the CoMFA and CoMSIA methods are described in Figure 3. The good linear relationships illustrated that the bioactivities predicted by the derived models are in agreement with the experimental data (see Figure 2), indicating that these models had satisfactory predictive capacity.

**Graphical interpretation of CoMFA and CoMSIA results**

The contour maps of CoMSIA and CoMFA are generated to determine regions in 3D space around molecules where changes in each field are predicted either it can increase or decrease the activity. The steric and electrostatic contour maps of CoMFA are shown in Figure 3. While electrostatic, Steric, hydrogen bond acceptor and hydrophobic contour

**Table 3. PLS Statistics of CoMFA and CoMSIA models**

| Model   | \(Q^2\) | \(R^2\) | \(S_{cv}\) | \(F\)   | \(N\) | \(r_{cv}^2\) | Fractions |
|---------|---------|---------|-----------|--------|------|-------------|-----------|
|         |         |         |           |        |      | Ster | Elec | Acc | Don | Hyd |
| CoMFA   | 0.70    | 0.94    | 0.20      | 13.56  | 4    | 0.89 | 0.606 | 0.194 | -   | -   | -   |
| CoMSIA  | 0.68    | 0.85    | 0.33      | 49.62  | 3    | 0.96 | 0.079 | 0.122 | 0.297| 0.00 | 0.502 |

\(R^2\): Non-cross-validated correlation coefficient.

\(Q^2\): Cross-validated correlation coefficient.

\(S_{cv}\): Standard error of the estimate.

\(N\): Optimum number of components.

\(r_{cv}^2\): External validation correlation coefficient.

\(F\): F-test value.

Advanced Pharmaceutical Bulletin, 2019, Volume 9, Issue 1 | 87
Figure 2. Plots of experimental and predicted pIC50 values for the total set in the CoMFA (A) and CoMSIA (B) models.

Figure 3. Contour maps of CoMFA with 2 Å grid spacing with compound 24. A) Electrostatic fields: blue contours show regions where groups with positive charges increase activity, while red contours indicate regions where groups with negative charges increase activity. B) Steric fields: green contours indicate regions where bulky groups increase activity, and yellow contours indicate regions where bulky groups decrease activity.

maps of CoMSIA are shown in Figure 4. Compound 4 and 24 are used as reference structures. All the contours represented default 80% and 20% level contributions for favored and disfavored regions, respectively.

CoMFA contour maps
Electrostatic interactions in comparative molecular field analysis method are represented by red and blue contours while steric interactions are presented by green and yellow contours. Bulky substituents are favored in green regions, while at yellow regions, they are unfavored. Blu regions indicate that positive charges are favored.

Figure 3 shows green and red contours around chlorine of quinoline compound (the active molecule), indicate that bulky groups with electron withdrawing character can increase the activity, the yellow and blue contours around dimethyl carbonyl of benzene compound (the inactive molecule), indicate that small groups with electron donating character are favored. These results explain why the compounds 22 and 24 with bulky and electron withdrawing groups around green and red contour maps present high activities, while compounds 6 and 9 with bulky and electron withdrawing around yellow and blue contour maps \((R_3 = \text{CH}_2\text{CICO})\) present low activities.

CoMSIA contour map
The CoMSIA steric and electrostatic field contour maps indicate that bulky groups with electron withdrawing character are only favored at \(R_3\) position, the blue and yellow contours at \(R_1\) and \(R_2\) positions indicate that small groups with electron donating character are favored (see Figure 4). This is similar to CoMFA contour maps results. The red contour around nitrogen and carbonyl groups indicates that groups with hydrogen bond donor character could increase the activity, while the purple contour at \(R_3\) position indicates that only groups with hydrogen bond acceptor character can increase the activity. Therefore, the huge yellow contour around the molecule shows the hydrophobic character of the active compound.

These results indicate that only hydrophobic compounds with bulky electron withdrawing groups at \(R_3\) position can increase the activity.

Y-Randomization
The Y-Randomization method is carried out to validate CoMFA and CoMSIA models. Several random shuffles of the dependent variable were performed; after every shuffle, a 3D-QSAR was developed and the obtained results are shown in Table 4. The low \(Q^2\) and \(r^2\) values indicate that the good result in our original CoMFA and CoMSIA models are not due to chance correlation.

Design for new molecules with anti-obesity activity
Relying on CoMFA and CoMSIA models, new molecules have been designed to enhance the activity (Table 5). These compounds were aligned to database using compound 24.
In Silico Exploration of Aryl Halides Analogues as Checkpoint Kinase 1 Inhibitors

The newly predicted structure A1 showed higher activity (pLC\textsubscript{50} = 3.28 and 3.37 for CoMFA and CoMSIA models respectively) than compound 24 (the most active compound of the series pLC\textsubscript{50} = 2.6).

Compounds with bulky electron withdrawing hydrophobic groups present high predicted activities, which means that the predicted compounds can be more effective that the compounds of the database.

To determine the stability and the interactions of these predicted molecules with the receptor, we applied surflex-docking.

**Docking results**

Molecular docking protocols are widely using to investigate the binding modes between the ligand derivatives and the receptor, which help understanding the 3D-QSAR study revealed by CoMFA/CoMSIA models. The target ligand taken from the crystal structure is redocked into the active site to validate the accuracy of molecular docking, the root mean square deviation (RMSD) value is 1.2 Å. Figure 5 shows the different top 10 positions of molecule 24 in the protein pocket, which present a stable conformation compared to compound 6 with scoring 3.7 and 1.2 respectively.

Subsequently, the most active compound 24 was docked into the ligand-binding pocket of Chk1 protein (code PDB: 6FC8), as described in Figure 6 the docking results shows alkyl and pi-alkyl bonds with LEU15; LEU137; ALA36; TYR86. In addition CYS87 residue presents halogen interaction with chlorine group, Van der Waals interaction between oxygen atom and VAL23 residue. The group amine –NH2 provided a hydrogen bond with SER147 residue and electrostatic interaction with ASP148 residue, which indicate that electro-withdrawing groups with hydrophobic character increase the stability of compound in the active protein pocket. Moreover, the results obtained by the docking had been compared with the OSAR results to verify mutually. These interactions match well with the results of H-bond acceptor/electrostatic contour maps.

![Figure 5](image.png)

**Figure 5.** The MOLCAD surface of the site within the compound 24. a) different positions of compound 24 in the receptor. b) stable position of compound 24 in the receptor.

![Figure 6](image.png)

**Figure 6.** Docking interactions of compound 24 as the active compound in database.

Figure 7 shows that compound A1 (proposed compound with hydrophobic character) present Alkyl and pi-Alkyl bonds with LEU15; LEU137; ALA36; TYR86. In addition CYS87 residue presents halogen interaction with chlorine group, Van der Waals interaction between oxygen atom and VAL23 residue. The group amine –NH2 provided a hydrogen bond with SER147 residue and electrostatic interaction with ASP148 residue, which indicate that electro-withdrawing groups with hydrophobic character increase the stability of compound in the active protein pocket. Moreover, the results obtained by the docking had been compared with the OSAR results to verify mutually. These interactions match well with the results of H-bond acceptor/electrostatic contour maps.

### Table 4. Q\textsuperscript{2} and r\textsuperscript{2} values after several Y-randomization tests

| Iteration | CoMFA | CoMSIA | CoMFA | CoMSIA |
|-----------|-------|--------|-------|--------|
|           | Q\textsuperscript{2} | r\textsuperscript{2} | Q\textsuperscript{2} | r\textsuperscript{2} |
| 1         | -0.37 | 0.59   | 0.21  | 0.35   |
| 2         | 0.34  | 0.62   | -0.07 | 0.22   |
| 3         | -0.18 | 0.10   | 0.21  | 0.61   |
| 4         | 0.12  | 0.32   | -0.19 | 0.02   |
| 5         | 0.14  | 0.26   | 0.05  | 0.28   |

### Table 5. Chemical structure of newly designed molecules and their predicted pLC\textsubscript{50} based on CoMFA and CoMSIA 3D-QSAR models

| No | Structure | Predicted pLC\textsubscript{50} | CoMFA | CoMSIA |
|----|-----------|---------------------------------|-------|--------|
| A1 | - O CONH\textsubscript{2} Me Cl Me Me OH | 3.28  | 3.37   |
| A2 | - O OMe Me Cl Me Me OH | 2.98  | 2.26   |
| A3 | - O CONe Me Cl Me Me OH | 2.85  | 2.27   |
| A4 | - O CF\textsubscript{3} Me Cl Me Me OH | 2.29  | 2.58   |

Advanced Pharmaceutical Bulletin, 2019, Volume 9, Issue 1 | 89
Drug-likeness or druggability

According to ‘Lipinski’s rule of five’, the lead compounds with poor absorption are known when there are more than 5 HBD, 10 HBA, the molecular weight higher than 500 Da and the calculated LogP (CLogP) is greater than 5. Moreover, an excellent bioavailability is likely for molecules with total polar surface area (TPSA) of ≤140 Å and rotatable bonds ≤10 (nrotb).

In this study; in silico evaluation of new proposed Chk1 inhibitors drugs shows good oral bioavailability. The calculated LogP values, the number of hydrogen bond acceptors (HBA) and hydrogen bond donors (HBD) agreed with Lipinski’s rule of five. Furthermore, TPSA, total hydrogen bond count and the number of rotatable bonds fell within the limit ranges (see Table 6). Drug molecules of molecular weight less than 500 Da are easily transported, diffuse and absorbed as compared to heavy molecules. Which indicate that the proposed molecules present good bioavailability. Moreover, ADMET method applied to determine their properties and therapeutic benefit because Lack of efficacy and unacceptable toxicity of the new drug are mainly associated with failures of drug discovery.

ADME and toxicity results

During the drug discovery effort many drugs are miscarried due to blood brain permeation failure, toxicity and poor efficacy. The purpose of preclinical ADMET is to eliminate weak candidates. This allows drug-development resources to be focused on fewer but more-likely-to-succeed drug candidates. In this review will be treated the applicability of QSAR methods for the prediction of the ADMET profile of the new lead compounds as chk1 inhibitors anti-cancer agents. Therefore virtual properties were investigated, Absorption, distribution, metabolism, excretion, and toxicity (ADMET), which are key players in drug development.

The pharmacokinetic (ADMET) properties of the studied leads were calculated using admetSAR and pKCSM predictors. Blood-brain barrier (BBB) penetration, HIA, Caco-2 cell permeability and Ames test are used to refine the drug likeness properties.

The main interfaces separating the central nervous system (CNS) and the blood circulation are known as the BBB and the blood-cerebrospinal fluid barrier. BBB permeation is an important property for medicinal chemistry since it determines which drugs can or cannot pass the BBB and thereby exert its effect on the brain. For a given compound logBB<-1 considered poorly distributed to the brain. Therefore, BBB permeability results in Table 7 show non-penetrating (BBB-) for compounds A1 and A2 as new chk1 inhibitors drugs.

It was also found that all tested compounds could be absorbed by the human intestine, but they cannot penetrate to Caco-2 (see Table 7). Nevertheless, the tested compounds proved to be potential substrates for P-glycoprotein (P-gp) which effluxes drugs and various compounds to undergo further metabolism and clearance resulting in therapeutic failure because the drug concentration would be lower than expected.

Inhibition of OCTs and OATs can affect drug-drug interactions in cases where a drug that is cleared by a particular renal transporter is coadministered with another drug which inhibits the same transporter. The result can reduce renal clearance, and that is not the case of these new proposed drugs.

The inhibition of cytochrome P450 may cause drug-drug interactions in which coadministered drugs fail to be metabolized and accumulate to toxic levels. Notwithstanding, some of the cytochrome P450 isoforms might be inhibited by one or more of the predicted compounds. Fortunately, the new Checkpoint kinases inhibitors did not show any acute toxicity or mutagenic effect, respecting Ames test data.

Conclusion

Several aromatic halides analogs were identified as potentially effective oral Chk1 inhibitors through a

### Table 6. Physicochemical parameters of the three lead compounds

|          | LogP  | MW    | TPSA  | HBD | HBA | nrotb |
|----------|-------|-------|-------|-----|-----|-------|
| Compound A1 | 2.02126 | 278.695 | 113.553 | 2   | 3   | 1     |
| Compound A2 | 3.01496 | 279.723 | 114.578 | 2   | 3   | 1     |
| Compound A3 | 2.82096 | 267.712 | 109.165 | 2   | 3   | 1     |
| Compound A4 | 3.83116 | 305.683 | 116.548 | 2   | 2   | 0     |
In Silico Exploration of Aryl Halides Analogues as Checkpoint Kinase 1 Inhibitors

### Table 7. Pharmacokinetic (ADMET) properties of the new anti-tuberculosis agents.

| Models                        | Compound1 | Compound2 | Compound3 | Compound4 |
|-------------------------------|-----------|-----------|-----------|-----------|
| Absorption                    |           |           |           |           |
| Blood-brain barrier (LogBB)   | -0.241    | -0.218    | 0.229     | 0.362     |
| Intestinal absorption (human)| 82.522    | 94.049    | 93.629    | 89.548    |
| Caco² permeability            | 0.246     | 0.972     | 1.181     | 1.269     |
| P-glycoprotein substrate      | Yes       | Yes       | Yes       | Yes       |
| P-glycoprotein inhibitor      | No        | No        | No        | No        |
| Renal OCT2 substrate          | No        | No        | No        | No        |

### Distribution and Metabolism

| Models                        | Compound1 | Compound2 | Compound3 | Compound4 |
|-------------------------------|-----------|-----------|-----------|-----------|
| CYP2D6 substrate              | No        | No        | No        | No        |
| CYP450 3A4 Substrate          | No        | No        | No        | No        |
| CYP1A2 inhibitor              | Yes       | Yes       | Yes       | Yes       |
| CYP 2C9 inhibitor             | No        | No        | No        | No        |
| CYP2D6 inhibitor              | Yes       | No        | No        | No        |
| CYP2C19 inhibitor             | No        | No        | No        | Yes       |
| CYP3A4 inhibitor              | No        | No        | No        | No        |

### Excretion and Toxicity

| Models                        | Compound1 | Compound2 | Compound3 | Compound4 |
|-------------------------------|-----------|-----------|-----------|-----------|
| Human ether-a-go-go-related gene inhibition | No | No | No | No |
| Ames toxicity                 | No        | No        | No        | No        |
| Carcinogens                   | Non-carcinogens | Non-carcinogens | Non-carcinogens | Non-carcinogens |
| Hepatotoxicity                | No        | No        | No        | No        |

Ethical Issues
Not applicable.

Conflict of Interest
The authors declare that there are no conflicts of interests.

Acknowledgments
We are grateful to the "Association Marocaine des Chimistes Théoriciens" (AMCT) for its pertinent help concerning the programs.

References
1. Roy K, Kar S, Das RN. Understanding the Basics of QSAR for Applications in Pharmaceutical Sciences and Risk Assessment. Academic Press; 2015. p. 1-479. doi: 10.1016/C2014-0-00286-9
2. Cramer RD, Patterson DE, Bunce JD. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 1988;110(18):5959-67. doi: 10.1021/ja00226a005
3. Klebe G, Abraham U, Mietzner T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem 1994;37(24):4130-46. doi: 10.1021/jm00050a010
4. Khan MAE, Ali MI, Hashem MA. Polymer-supported Ammonium Dichlorobromide(I) Reagent Promoted Halogenation of Hydroxy and Amino Substituted Aromatic Compounds. J Bang Chem Soc 2009;22(1):55-65.
5. Carrassa L, Damia G. Unleashing Chk1 in cancer therapy. Cell Cycle 2011;10(13):2121-8. doi: 10.4161/cc.10.13.16398
6. Dearden JC. In silico prediction of ADMET properties: how far have we come? Expert Opin Drug Metab Toxicol 2007;3(5):635-9. doi: 10.1517/17425255.3.5.635
7. Sybyl-X Molecular Modeling Software Packages, Version 2.0. St. Louis, MO, USA: TRIPOS Associates, Inc; 2012.
8. Dassault Systèmes BIOVIA, Discovery Studio Modeling Environment, Release 2017. San Diego: Dassault Systèmes; 2016.
9. Cao D, Wang J, Zhou R, Li Y, Yu H, Hou T. ADMET evaluation in drug discovery. 11. PharmacoKinetics Knowledge Base (PKKB): a comprehensive database of pharmacokinetic and toxic properties for drugs. J Chem Inf Model 2012;52(5):1132-7. doi: 10.1021/ci300112j
10. Pires DE, Blundell TL, Ascher DB. pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J Med Chem 2015;58(9):4066-72. doi: 10.1021/acs.jmedchem.5b00104
11. Clark M, Cramer RD, Van Opdenbosch N. Validation of the general purpose tripos 5.2 force field. J Comput Chem

Advanced Pharmaceutical Bulletin, 2019, Volume 9, Issue 1 | 91
Dang W, Muto Y, Inoue M, Kigawa T, Shirouzu M, Terada T, et al. Solution structure of the RRM_1 domain of NCL protein. Protein Data Bank; 2005. doi: 10.2210/pdb2FC8/pdb

Jain AN. Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. *J Med Chem* 2003;46(4):499-511. doi: 10.1021/jm020406h

Sun J, Cai S, Mei H, Li J, Yan N, Wang Y. Docking and 3D QSAR study of thiourea analogs as potent inhibitors of influenza virus neuraminidase. *J Mol Model* 2010;16(12):1809-18. doi: 10.1007/s00894-010-0685-9

Al Y, Wang ST, Sun PH, Song FJ. Molecular modeling studies of 4,5-dihydro-1H-pyrazolo[4,3-h] quinazoline derivatives as potent CDK2/Cyclin A inhibitors using 3D-QSAR and docking. *Int J Mol Sci* 2010;11(10):3705-24. doi: 10.3390/ijms11103705

Lan P, Chen WN, Chen WM. Molecular modeling studies on imidazo [4, 5-b] pyridine derivatives as Aurora A kinase inhibitors using 3D-QSAR and docking approaches. *Eur J Med Chem* 2011;46(1):77-94. doi: 10.1016/j.ejmech.2010.07.017

Lan P, Chen WN, Xiao GK, Sun PH, Chen WM. 3D-QSAR and docking studies on pyrazolo [4, 3-h] carboxamide derivatives as cyclin-dependent kinase 2 (CDK2) inhibitors. *Bioorg Med Chem Lett* 2010;20(22):6764-72. doi: 10.1016/j.bmcl.2010.08.131

Caldwell GW, Yan Z, Tang W, Dangupta M, Hasting B. ADMET optimization and toxicity assessment in early- and late-phase drug discovery. *Curr Top Med Chem* 2009;9(11):965-80. doi: 10.2174/156802609789630929

Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Adv Drug Deliv Rev* 2001;46(1-3):3-26. doi: 10.1016/S0169-409X(00)00129-0

Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. *J Med Chem* 2002;45(12):2615-23. doi: 10.1021/jm020017n

Srimai V, Ramesh M, Satya Parameshwar K, Parthasarathy T. Computer-aided design of selective Cytochrome P450 inhibitors and docking studies on alkyl resorcinol derivatives. *Med Chem Res* 2013;22(11):5314-23. doi: 10.1007/s00044-013-0532-5

Upadhyay RK. Drug delivery systems, CNS protection, and the blood brain barrier. *Biomed Res Int* 2014;2014:869269. doi: 10.1155/2014/869269

Ankomah P, Levin BR. Two-drug antimicrobial chemotherapy: a mathematical model and experiments with *Mycobacterium marinum*. *PLoS Pathog* 2012;8(1):e1002487. doi: 10.1371/journal.ppat.1002487

Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. *Am Fam Physician* 2007;76(3):391-6.